

Afschin Gandjour

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4436799/publications.pdf>

Version: 2024-02-01

113
papers

1,400
citations

361413

20
h-index

434195

31
g-index

121
all docs

121
docs citations

121
times ranked

1604
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-effectiveness of future lockdown policies against the COVID-19 pandemic. <i>Health Services Management Research</i> , 2023, 36, 51-62.	1.7	8
2	The clinical and economic value of a successful shutdown during the SARS-CoV-2 pandemic in Germany. <i>Quarterly Review of Economics and Finance</i> , 2022, 84, 502-509.	2.7	15
3	Pharmaceutical spending and early-stage innovation in EU countries. <i>Industry and Innovation</i> , 2022, 29, 1141-1170.	3.1	2
4	Benefits, risks, and cost-effectiveness of COVID-19 self-tests from a consumer's perspective. <i>BMC Health Services Research</i> , 2022, 22, 47.	2.2	6
5	Nephron overload as a therapeutic target to maximize kidney lifespan. <i>Nature Reviews Nephrology</i> , 2022, 18, 171-183.	9.6	28
6	Vaccination Mandates, Physically Forced Vaccination, and Rationing in the Intensive Care Unit: Searching for Ethical Coherence in the COVID-19 Pandemic. <i>American Journal of Bioethics</i> , 2022, 22, 11-14.	0.9	2
7	Value-based pricing of a COVID-19 vaccine. <i>Quarterly Review of Economics and Finance</i> , 2022, 84, 1-8.	2.7	3
8	Optimal Sample Size Calculation for Clinical Research under a Budget Constraint. <i>Medical Decision Making</i> , 2022, 42, 417-418.	2.4	0
9	Demonstrating the value of cancer biomarkers at the population level. <i>European Journal of Health Economics</i> , 2022, , .	2.8	0
10	How Many Intensive Care Beds are Justifiable for Hospital Pandemic Preparedness? A Cost-effectiveness Analysis for COVID-19 in Germany. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 181-190.	2.1	29
11	Deterministic Sensitivity Analysis Under Ignorance. <i>Pharmacoeconomics</i> , 2021, 39, 1197-1198.	3.3	2
12	Financial Incentives in the Path to Recovery from the COVID-19 Pandemic. <i>Applied Health Economics and Health Policy</i> , 2021, 20, 5.	2.1	2
13	A parsimonious model to validate cost-effectiveness analyses on preventive health care. <i>BMC Health Services Research</i> , 2021, 21, 1213.	2.2	0
14	The price of curing cancer. <i>BMC Health Services Research</i> , 2021, 21, 1328.	2.2	6
15	Trends in rates of orthopedic surgery in Germany: the good, the bad, and the ugly. <i>European Journal of Health Economics</i> , 2020, 21, 663-664.	2.8	0
16	Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany. <i>Applied Health Economics and Health Policy</i> , 2020, 18, 109-125.	2.1	4
17	Defining Comparators According to IQWiG's Efficiency-Frontier Method. <i>Value in Health</i> , 2020, 23, 674-675.	0.3	0
18	Predictors of negotiated prices for new drugs in Germany. <i>European Journal of Health Economics</i> , 2020, 21, 1049-1057.	2.8	15

#	ARTICLE	IF	CITATIONS
19	Costs of patients with chronic kidney disease in Germany. PLoS ONE, 2020, 15, e0231375.	2.5	30
20	A proportional rule for setting reimbursement prices of new drugs and its mathematical consistency. BMC Health Services Research, 2020, 20, 240.	2.2	7
21	Willingness to pay for new medicines: a step towards narrowing the gap between NICE and IQWiG. BMC Health Services Research, 2020, 20, 343.	2.2	24
22	Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results. PLoS ONE, 2020, 15, e0236543.	2.5	3
23	FP396 Costs of patients with Chronic Kidney Disease in Germany. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
24	Pharmaceutical expenditure and gross domestic product: Evidence of simultaneous effects using a two-step instrumental variables strategy. Health Economics (United Kingdom), 2019, 28, 101-122.	1.7	6
25	Comment on "Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany". European Journal of Health Economics, 2018, 19, 471-472.	2.8	1
26	Patient preferences: a Trojan horse for evidence-based medicine?. European Journal of Health Economics, 2018, 19, 167-172.	2.8	4
27	Budgetary Impact and Cost Drivers of Drugs for Rare and Ultrarare Diseases. Value in Health, 2018, 21, 525-531.	0.3	32
28	Underuse of innovative medicines in Germany: A justification for government intervention?. Health Policy, 2018, 122, 1283-1286.	3.0	1
29	Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany. Pharmacoeconomics, 2018, 36, 1285-1296.	3.3	24
30	Comment on: "Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation". Pharmacoeconomics, 2017, 35, 603-604.	3.3	2
31	Comment on: "The Cost Effectiveness of High-Dose Versus Conventional Haemodialysis: A Systematic Review". Applied Health Economics and Health Policy, 2016, 14, 729-730.	2.1	1
32	Limiting Free Pricing of New Innovative Drugs After Launch: A Necessity for Payers?. Applied Health Economics and Health Policy, 2016, 14, 507-509.	2.1	1
33	Comment on: "The Role of Chronic Disease, Obesity, and Improved Treatment and Detection in Accounting for the Rise in Healthcare Spending Between 1987 and 2011". Applied Health Economics and Health Policy, 2016, 14, 241-241.	2.1	1
34	Should Cost-Effectiveness Analysis Include the Cost of Consumption Activities? AN Empirical Investigation. Health Economics (United Kingdom), 2016, 25, 249-256.	1.7	1
35	Prioritizing health services research: an economic perspective. European Journal of Health Economics, 2016, 17, 375-377.	2.8	1
36	A model to optimize investments in health technologies, quality of care and research. Applied Economics, 2015, 47, 2031-2039.	2.2	2

#	ARTICLE	IF	CITATIONS
37	Osteoporosis in German men: a cost-of-illness study. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 531-537.	1.4	6
38	Convergence of decision rules for value-based pricing of new innovative drugs. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 209-213.	1.4	8
39	Avoiding research waste through cost-effectiveness analysis: the example of medication adherence-enhancing interventions. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 43-46.	1.4	0
40	A simulation model to estimate cost-offsets for a disease-management program for chronic kidney disease. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 341-347.	1.4	5
41	Comment on: "Impact and cost-effectiveness of a universal strategy to promote physical activity in primary care". <i>European Journal of Health Economics</i> , 2015, 16, 451-452.	2.8	0
42	Drug pricing and control of health expenditures: a comparison between a proportional decision rule and a cost-per-QALY rule. <i>International Journal of Health Planning and Management</i> , 2015, 30, 395-402.	1.7	8
43	Comment on: "Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy". <i>Pharmacoeconomics</i> , 2015, 33, 981-982.	3.3	2
44	Commentary to: Cost of poor adherence to anti-hypertensive therapy in five European countries. <i>European Journal of Health Economics</i> , 2015, 16, 907-907.	2.8	1
45	Cost-Effectiveness Analysis of High-Efficiency Hemodiafiltration Versus Low-Flux Hemodialysis Based on the Canadian Arm of the CONTRAST Study. <i>Applied Health Economics and Health Policy</i> , 2015, 13, 647-659.	2.1	19
46	Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 171-179.	1.4	15
47	Considering productivity loss in cost-effectiveness analysis: a new approach. <i>European Journal of Health Economics</i> , 2014, 15, 787-790.	2.8	3
48	Ethical Objections Against Including Life-Extension Costs in Cost-Effectiveness Analysis: A Consistent Approach. <i>Applied Health Economics and Health Policy</i> , 2014, 12, 471-476.	2.1	4
49	Welfare gains and losses caused by clinical practice guidelines. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 27-33.	1.4	3
50	Public acceptance of different approaches to determine drug reimbursement prices and whether it is influenced by framing. <i>International Journal of Public Sector Management</i> , 2014, 27, 501-511.	1.8	3
51	Determining the price for pharmaceuticals in Germany: comparing a shortcut for IQWiG's efficiency frontier method with the price set by the manufacturer for ticagrelor. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 123-129.	1.4	7
52	Health care expenditures from living longer"how much do they matter. <i>International Journal of Health Planning and Management</i> , 2014, 29, 43-51.	1.7	4
53	Comment on: "Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines". <i>Pharmacoeconomics</i> , 2014, 32, 1245-1246.	3.3	2
54	Capturing Disutility from Waiting Time. <i>Pharmacoeconomics</i> , 2014, 32, 423-424.	3.3	2

#	ARTICLE	IF	CITATIONS
55	Reference Pricing and Price Negotiations for Innovative New Drugs. <i>Pharmacoeconomics</i> , 2013, 31, 11-14.	3.3	13
56	Validation of Models That Estimate the Cost-Effectiveness of Improving Patient Adherence. <i>Value in Health</i> , 2013, 16, 1170-1171.	0.3	1
57	Internal validation of models with several interventions. <i>European Journal of Health Economics</i> , 2013, 14, 901-909.	2.8	3
58	To Treat or Not to Treat? Cost-Effectiveness of Ace Inhibitors in Non-Diabetic Advanced Renal Disease - a Dutch Perspective. <i>Kidney and Blood Pressure Research</i> , 2013, 37, 168-180.	2.0	12
59	A theoretical and empirical investigation into the willingness-to-pay function for new innovative drugs by Germany's health technology assessment agency (IQWiG). <i>Health Services Management Research</i> , 2013, 26, 103-109.	1.7	2
60	Comparing the validity of different measures of illness severity: a hospital-level analysis for acute myocardial infarction. <i>Health Services Management Research</i> , 2012, 25, 138-143.	1.7	4
61	Simplifying rules for optimal allocation of preventive care resources. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 231-235.	1.4	1
62	Cost-Effectiveness of Different Strategies for Selecting and Treating Individuals at Increased Risk of Osteoporosis or Osteopenia: A Systematic Review. <i>Value in Health</i> , 2012, 15, 284-298.	0.3	21
63	Cost-effectiveness of preventing weight gain and obesity: what we know and what we need to know. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 297-305.	1.4	7
64	Presenting Germany's drug pricing rule as a cost-per-QALY rule. <i>Health Care Management Science</i> , 2012, 15, 103-107.	2.6	11
65	Germany's Decision Rule for Setting Ceiling Prices of Drugs. <i>Applied Health Economics and Health Policy</i> , 2011, 9, 65-71.	2.1	22
66	Cost-Effectiveness of Implantable Defibrillators after Myocardial Infarction Based on 8-Year Follow-Up Data (MADIT II). <i>Value in Health</i> , 2011, 14, 812-817.	0.3	18
67	Cost Effectiveness of Secondary vs Tertiary Prevention for Post-Menopausal Osteoporosis. <i>Applied Health Economics and Health Policy</i> , 2011, 9, 259-273.	2.1	4
68	A new prize system for drug innovation. <i>Health Policy</i> , 2011, 102, 170-177.	3.0	15
69	Empirical Validation of Patient versus Population Preferences in Calculating QALYs. <i>Health Services Research</i> , 2011, 46, 1562-1574.	2.0	13
70	Protocol-driven costs in trial-based pharmacoeconomic analyses. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011, 11, 673-675.	1.4	3
71	Cost-effectiveness of angiotensin-converting enzyme inhibitors in nondiabetic advanced renal disease. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011, 11, 215-223.	1.4	5
72	The German method for setting ceiling prices for drugs: in some cases less data are required. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011, 11, 403-409.	1.4	11

#	ARTICLE	IF	CITATIONS
73	Cost-Effectiveness of Angiotensin-Converting Enzyme Inhibitors for the Prevention of Diabetic Nephropathy in The Netherlands – A Markov Model. PLoS ONE, 2011, 6, e26139.	2.5	20
74	Investment in quality improvement: how to maximize the return. Health Economics (United Kingdom), 2010, 19, 31-42.	1.7	7
75	A model to predict the cost-effectiveness of disease management programs. Health Economics (United) Tj ETQq1, 1, 0.784314 rgBT	1.7	12
76	Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany. International Journal of Technology Assessment in Health Care, 2010, 26, 62-70.	0.5	13
77	Theoretical Foundation of Patient v. Population Preferences in Calculating QALYs. Medical Decision Making, 2010, 30, E57-E63.	2.4	41
78	Costs of dialysis—a regional population-based analysis. Nephrology Dialysis Transplantation, 2010, 25, 1647-1652.	0.7	66
79	The additive utility assumption of the QALY model revisited. Journal of Health Economics, 2010, 29, 325-328.	2.7	5
80	Ageing diseases – do they prevent preventive health care from saving costs?. Health Economics (United) Tj ETQq0 0,0 rgBT /O	1.7	13
81	Cost-Effectiveness of Using Clinical Risk Factors with and without DXA for Osteoporosis Screening in Postmenopausal Women. Value in Health, 2009, 12, 1106-1117.	0.3	26
82	Economic evaluation of Sinfrontal® in the treatment of acute maxillary sinusitis in adults. Applied Health Economics and Health Policy, 2009, 7, 181-191.	2.1	15
83	Mutual dependency between capabilities and functionings in Amartya Sen's capability approach. Social Choice and Welfare, 2008, 31, 345-350.	0.8	25
84	Incorporating feelings related to the uncertainty about future health in utility measurement. Health Economics (United Kingdom), 2008, 17, 1207-1213.	1.7	7
85	Cost-Effectiveness of Preventing Hip Fractures by Hip Protectors in Elderly Institutionalized Residents in Germany. Value in Health, 2008, 11, 1088-1095.	0.3	18
86	Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women. Applied Health Economics and Health Policy, 2008, 6, 113-135.	2.1	13
87	Loss Aversion and Cost Effectiveness of Healthcare Programmes. Pharmacoeconomics, 2008, 26, 895-898.	3.3	6
88	What drives US competitiveness in mathematics and science?. Educational Studies, 2008, 34, 269-270.	2.4	0
89	Is it Rational to Pursue Utilitarianism?. Ethical Perspectives, 2007, 14, 139-158.	0.1	2
90	A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness. Health Policy, 2007, 83, 257-267.	3.0	31

#	ARTICLE	IF	CITATIONS
91	Cost-effectiveness of referrals to high-volume hospitals: An analysis based on a probabilistic Markov model for hip fracture surgeries. <i>Health Care Management Science</i> , 2006, 9, 359-369.	2.6	15
92	Consumption costs and earnings during added years of life - a reply to Nyman. <i>Health Economics (United Kingdom)</i> , 2006, 15, 315-317.	1.7	30
93	European Comparison of Costs and Quality in the Treatment of Acute Back Pain. <i>Spine</i> , 2005, 30, 969-975.	2.0	23
94	Technology assessment in dentistry: A comparison of the longevity and cost-effectiveness of inlays. <i>International Journal of Technology Assessment in Health Care</i> , 2005, 21, 319-325.	0.5	4
95	How Much Does It Cost to Change the Behavior of Health Professionals? A Mathematical Model and an Application to Academic Detailing. <i>Medical Decision Making</i> , 2005, 25, 341-347.	2.4	12
96	Impact of Demographic Changes on Healthcare Expenditures and Funding in the EU. <i>Applied Health Economics and Health Policy</i> , 2005, 4, 1-4.	2.1	3
97	Does prevention save costs?. <i>Journal of Health Economics</i> , 2005, 24, 715-724.	2.7	48
98	Cost-Effectiveness Analysis of Different Screening Procedures for Type 2 Diabetes: The KORA Survey 2000. <i>Diabetes Care</i> , 2004, 27, 2120-2128.	8.6	28
99	Direct Costs of Care in Germany for Children and Adolescents with Diabetes Mellitus in the Early Course After Onset. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2004, 17, 1551-9.	0.9	16
100	Costs and quality in the treatment of acute depression in primary care: a comparison between England, Germany and Switzerland. <i>International Clinical Psychopharmacology</i> , 2004, 19, 201-208.	1.7	7
101	Utilitarian Theories Reconsidered: Common Misconceptions, More Recent Developments, and Health Policy Implications. <i>Health Care Analysis</i> , 2003, 11, 229-244.	2.2	23
102	Inductive reasoning in medicine: lessons from Carl Gustav Hempel's "inductive-statistical" model. <i>Journal of Evaluation in Clinical Practice</i> , 2003, 9, 161-169.	1.8	5
103	The Practice-Makes-Perfect Hypothesis in the Context of Other Production Concepts in Health Care. <i>American Journal of Medical Quality</i> , 2003, 18, 171-175.	0.5	20
104	When Is It Worth Introducing a Quality Improvement Program? A Mathematical Model. <i>Medical Decision Making</i> , 2003, 23, 518-525.	2.4	28
105	A Cost-Effectiveness Model of Screening Strategies for Amblyopia and Risk Factors and Its Application in a German Setting. <i>Optometry and Vision Science</i> , 2003, 80, 259-269.	1.2	13
106	Appropriateness of invasive cardiovascular interventions in German hospitals (2000-2001): an evaluation using the RAND appropriateness criteria. <i>European Journal of Cardio-thoracic Surgery</i> , 2003, 24, 571-577.	1.4	8
107	Threshold Volumes Associated With Higher Survival in Health Care. <i>Medical Care</i> , 2003, 41, 1129-1141.	2.4	103
108	An evidence-based disease-management program for patients with diabetic nephropathy. <i>Journal of Nephrology</i> , 2003, 16, 500-10.	2.0	2

#	ARTICLE	IF	CITATIONS
109	An Evidence-Based Evaluation of Quality and Efficiency Indicators. <i>Quality Management in Health Care</i> , 2002, 10, 41-52.	0.8	36
110	Is subjective well-being a useful parameter for allocating resources among public interventions?. <i>Health Care Analysis</i> , 2001, 9, 437-447.	2.2	8
111	Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: a decision analysis based on cost reimbursement in Germany. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 1441-1456.	2.1	62
112	Review of Quality-of-Life Evaluations in Patients with Angina Pectoris. <i>Pharmacoeconomics</i> , 1999, 16, 141-152.	3.3	37
113	Comment on "Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective". <i>Pharmacoeconomics</i> , 0, , .	3.3	0